Please enter your license information:
CV Safety Outcomes
CAROLINA CV events graph full text
- CAROLINA CV events graph showing the demonstrated time to first occurrence of CV death, nonfatal MI or nonfatal stroke (primary composite CV endpoint) for Trajenta® (n=3,023) and glimepiride (n=3,010).
- Y-axis shows the patients with event from 0 to 20%. Years from 0.0 to 7.0 is on the x-axis.
- The hazard ratio was 0.98 (95% confidence interval: 0.84 to 1.14), p<0.001 for non-inferiority. Subjects with events was 11.8% (n=356) for Trajenta® vs. 12.0% (n=362) for glimepiride.
- Patients at risk for Trajenta®: 3,023 at Year 0.0, 2,957 at Year 0.5, 2,901 at Year 1.0, 2,846 at Year 1.5, 2,803 at Year 2.0, 2,762 at Year 2.5, 2,725 at Year 3.0, 2,679 at Year 3.5, 2,627 at Year 4.0, 2,582 at Year 4.5, 2,534 at Year 5.0, 2,451 at Year 5.5, 1,830 at Year 6.0, 1,040 at Year 6.5 and 213 at Year 7.0.
- Patients at risk for glimepiride: 3,010 at Year 0.0, 2,940 at Year 0.5, 2,890 at Year 1.0, 2,833 at Year 1.5, 2,797 at Year 2.0, 2,757 at Year 2.5, 2,710 at Year 3.0, 2,662 at Year 3.5, 2,618 at Year 4.0, 2,569 at Year 4.5, 2,509 at Year 5.0, 2,414 at Year 5.5, 1,865 at Year 6.0, 1,020 at Year 6.5 and 207 at Year 7.0.
Are you thinking Trajenta®?
![Healthcare professional and patient Healthcare professional and patient](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/login-banner-updated.png)
Are you a Canadian
View coverage details for Trajenta® and Jentadueto®
![Map of Canada Map of Canada](https://pro.boehringer-ingelheim.com/ca/products/trajenta/images/check-coverage-icon.png)